Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874534 · ClinicalTrials.gov registry record · NA
Development of a Novel Transdiagnostic Intervention for Anhedonia - R61 Phase
A NA study of Anhedonia, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT02874534: Completed NA study of Anhedonia, sponsored by University of North Carolina, Chapel Hill.
NCT02874534 is a NA study of Anhedonia that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 57 participants, below the 108-participant average among 21 other Anhedonia trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02874534, a NA study of Anhedonia, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA), using ultra-high field functional neuroimaging. There is a critical need for a validated treatment that specifically targets anhedonia, and this project will evaluate the effects of this new treatment on anhedonia and will establish how this treatment impacts brain systems that mediate reward processing, clinical symptoms of anhedonia, functional outcomes, and behavioral indices of reward processing. This work will also identify brain targets by which future novel anhedonia treatment may be evaluated.
Primary Outcome
Change due to BATA, relative to MBCT, from baseline in right caudate nucleus activation during the anticipation phase of the Monetary Incentive Delay (MID) task assessed by Functional Magnetic Resonance Imaging (fMRI). The BOLD (Blood Oxygen Level-Dependent signal change is expressed as a z-score that represents the magnitude of change relative to baseline. A score of 0 would correspond to no change, and a score of 1 would represent 1 standard deviation of change. The difference in z-scores betw
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Activation
- BEHAVIORAL Mindfulness Treatment
Study Locations (1)
North Carolina
- UNC Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2019-07-31 |
| Phase | NA |
What the finished NCT02874534 record still lists
NCT02874534 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 108-participant average among 21 other Anhedonia trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Anhedonia appearing as the primary indexed condition, and to 2 interventions - of which Behavioral Activation is the first listed.
NCT02874534 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02874534 about?
NCT02874534 is a clinical study titled "Development of a Novel Transdiagnostic Intervention for Anhedonia - R61 Phase". The overall goal of this project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA), using ultra-high field functional neuroimaging. There is a critical need for a validated treatment that specifically targets anhedonia, and thi...
What is the current status of trial NCT02874534?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2017-06-22. Estimated completion is 2019-07-31.
What conditions does trial NCT02874534 study?
This clinical trial studies the following conditions: Anhedonia.
What interventions are being tested in trial NCT02874534?
The interventions under investigation include: Behavioral Activation (BEHAVIORAL), Mindfulness Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT02874534?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02874534 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anhedonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02874534's enrollment target sits among peer trials
57 18th of 21 higher than 4 of 21 other Anhedonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anhedonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression
RECRUITING · NA
-
Get ActivE Study for At-risk Youth
RECRUITING · NA
-
Reward Processing and Exposure Therapy for Social Anxiety Disorder
RECRUITING · NA
-
Psychotherapy Effects on Reward Processing in PTSD
RECRUITING · NA
-
Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression
RECRUITING · NA
-
Geolocation Positional System (GPS) Experience
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI